A Study of LY3857210 in Healthy Participants
Trial Summary
Do I have to stop taking my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. However, since the study involves healthy participants, it's possible that you may need to avoid certain medications. Please check with the study team for specific guidance.
What is the purpose of this trial?
This trial tests a new drug, LY3857210, in healthy people to see how it behaves in the brain using special brain scans. The study also checks if the drug is safe and tolerable.
Research Team
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Principal Investigator
Eli Lilly and Company
Eligibility Criteria
Inclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive a single oral dose of LY3857210 and undergo PET scans to measure brain receptor occupancy
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- LY3857210
Find a Clinic Near You
Who Is Running the Clinical Trial?
Eli Lilly and Company
Lead Sponsor
Dr. Daniel Skovronsky
Eli Lilly and Company
Chief Medical Officer since 2018
MD from Harvard Medical School
David A. Ricks
Eli Lilly and Company
Chief Executive Officer since 2017
BSc from Purdue University, MBA from Indiana University